Robert Wasserman
Stock Analyst at Benchmark
(3.34)
# 949
Out of 5,179 analysts
119
Total ratings
48.62%
Success rate
2.29%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Upgrades: Buy | $95 | $85.33 | +11.33% | 13 | Feb 20, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $61.63 | +46.03% | 11 | Feb 19, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $175 → $220 | $195.48 | +12.54% | 12 | Nov 7, 2025 | |
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $56.04 | -1.86% | 7 | Nov 3, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $100 → $38 | $6.03 | +521.89% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $50.95 | +47.20% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $8.15 | +84.05% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.51 | +297.35% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $30.17 | +16.01% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $3.27 | - | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $18.59 | +61.38% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $2.90 | +72.71% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $7.93 | +51.32% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.58 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $110.12 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $3.16 | +26.58% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $100 | $2.43 | +4,015.23% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.76 | +2,617.39% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $181.52 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $473.36 | +22.53% | 1 | Jul 16, 2021 |
Integer Holdings
Feb 20, 2026
Upgrades: Buy
Price Target: $95
Current: $85.33
Upside: +11.33%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Buy
Price Target: $75 → $90
Current: $61.63
Upside: +46.03%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $175 → $220
Current: $195.48
Upside: +12.54%
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $56.04
Upside: -1.86%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $100 → $38
Current: $6.03
Upside: +521.89%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $50.95
Upside: +47.20%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $8.15
Upside: +84.05%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.51
Upside: +297.35%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $30.17
Upside: +16.01%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $3.27
Upside: -
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $18.59
Upside: +61.38%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $2.90
Upside: +72.71%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $7.93
Upside: +51.32%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $1.58
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $110.12
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $3.16
Upside: +26.58%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $100
Current: $2.43
Upside: +4,015.23%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.76
Upside: +2,617.39%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $181.52
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $473.36
Upside: +22.53%